Onpharma

SCOPE
1) Create a lidocaine buffing device that can be mixed by the end-user prior to patient application. 2) Manufacture the device at high volumes. 3) Develop fully disposable Gen 2 device.
OUTCOME
The device attained 510(k) approval in two years, on a tight budget. Onpharma was acquired by a strategic partner in 2014, and then spun out in 2018 for next-generation development. Phoenix DeVentures has manufactured more than 2.5 million units as of 2023.

Meet Our Team

Get in touch with us today to see how we can help you achieve your goals.